Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research ...

Wall Street analysts expect 10x Genomics (TXG) to post quarterly loss of $0.32 per share in its upcoming report, which indicates a year-over-year increase of 22%. Revenues are expected to be $158. ...

10x Genomics (NASDAQ:TXG) just reported results for the first quarter of 2024. 10x Genomics reported earnings per share of -50 cents. This met the analyst estimate for EPS of -50 cents.

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa ...

Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties 10x Genomics reported a Q4 EPS loss of $(0.40), missing estimates ...

Short interest in 10x Genomics Inc (NASDAQ:TXG) increased during the last reporting period, rising from 6.60M to 7.61M. This put 8.23% of the company's publicly available shares short. Short ...

View 10x Genomics, Inc. (TXG) current and estimated P/E ratio data provided by Seeking Alpha.